Principal Investigator
James Hoffman
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231300
Clinical Trial Summary
An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647